ZA201402492B - Polymorphic form of pridopidine hydrochloride - Google Patents
Polymorphic form of pridopidine hydrochlorideInfo
- Publication number
- ZA201402492B ZA201402492B ZA2014/02492A ZA201402492A ZA201402492B ZA 201402492 B ZA201402492 B ZA 201402492B ZA 2014/02492 A ZA2014/02492 A ZA 2014/02492A ZA 201402492 A ZA201402492 A ZA 201402492A ZA 201402492 B ZA201402492 B ZA 201402492B
- Authority
- ZA
- South Africa
- Prior art keywords
- polymorphic form
- pridopidine hydrochloride
- pridopidine
- hydrochloride
- polymorphic
- Prior art date
Links
- YGRHOYQMBLLGEV-UHFFFAOYSA-N 4-(3-methylsulfonylphenyl)-1-propylpiperidine;hydrochloride Chemical compound Cl.C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGRHOYQMBLLGEV-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201170496 | 2011-09-07 | ||
| US201161533550P | 2011-09-12 | 2011-09-12 | |
| PCT/EP2012/067371 WO2013034622A1 (en) | 2011-09-07 | 2012-09-06 | Polymorphic form of pridopidine hydrochloride |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201402492B true ZA201402492B (en) | 2015-07-29 |
Family
ID=47831564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2014/02492A ZA201402492B (en) | 2011-09-07 | 2014-04-04 | Polymorphic form of pridopidine hydrochloride |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9006445B2 (https=) |
| EP (1) | EP2753603B1 (https=) |
| JP (2) | JP6189299B2 (https=) |
| KR (1) | KR20140075703A (https=) |
| CN (1) | CN103958469B (https=) |
| AU (1) | AU2012306386B2 (https=) |
| BR (1) | BR112014005389A8 (https=) |
| CA (1) | CA2847736A1 (https=) |
| EA (1) | EA023462B1 (https=) |
| ES (1) | ES2639052T3 (https=) |
| IL (1) | IL231149A0 (https=) |
| MX (1) | MX343620B (https=) |
| WO (1) | WO2013034622A1 (https=) |
| ZA (1) | ZA201402492B (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| SI2146961T1 (sl) | 2007-04-12 | 2014-08-29 | IVAX International GmbH | N-oksidni in/ali di-N-oksidni derivati stabilizatorjev/modulatorjev dopaminskega receptorja, ki izkazujejo izboljšane profile kardiovaskularnih stranskih učinkov |
| SG188298A1 (en) | 2010-09-03 | 2013-04-30 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| MX347209B (es) | 2011-12-08 | 2017-04-19 | Teva Pharmaceuticals Int Gmbh | La sal de bromhidrato de pridopidina. |
| HK1206297A1 (en) | 2012-04-04 | 2016-01-08 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for combination therapy |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| PE20160195A1 (es) | 2013-06-21 | 2016-05-14 | Teva Pharmaceuticals Int Gmbh | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| EP3236964A4 (en) * | 2014-12-22 | 2018-09-19 | Teva Pharmaceuticals International GmbH | L-tartrate salt of pridopidine |
| EP4282479A3 (en) | 2015-02-25 | 2024-02-21 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| WO2017048457A1 (en) * | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| US11738012B2 (en) | 2016-02-24 | 2023-08-29 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
| WO2018039475A1 (en) | 2016-08-24 | 2018-03-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for treating dystonias |
| ES3025836T3 (en) | 2016-08-24 | 2025-06-09 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating functional decline |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| CA3050700C (en) | 2017-01-20 | 2023-10-03 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for the treatment of fragile x syndrome |
| EP3357909A1 (en) | 2017-02-02 | 2018-08-08 | Sandoz AG | Crystalline 4-[3-(methylsulfonyl)phenyl]-1-propyl-piperidine |
| HRP20251431T1 (hr) | 2017-08-14 | 2026-01-02 | Prilenia Neurotherapeutics Ltd. | Liječenje amiotrofične lateralne skleroze pridopidinom |
| EP3675830A1 (en) | 2017-08-30 | 2020-07-08 | Prilenia Neurotherapeutics Ltd. | High concentration dosage forms of pridopidine |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| AU2018329628B2 (en) * | 2017-09-08 | 2021-04-22 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| EP3920924A4 (en) | 2019-02-04 | 2022-11-16 | Prilenia Neurotherapeutics Ltd. | LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904723D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| GB0329236D0 (en) * | 2003-12-17 | 2004-01-21 | Arakis Ltd | Crystalline forms of (+)- and (-)- erthro-mefloquine hydrochloride |
| JP2008501749A (ja) | 2004-06-08 | 2008-01-24 | ニューロサーチ スウェーデン アクチボラゲット | ドーパミン及びセロトニン神経伝達のモジュレーターとしての新規なジ置換フェニルピペリジン |
| CA2584831C (en) * | 2004-10-13 | 2013-09-17 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
| SE529246C2 (sv) | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| TW200804241A (en) * | 2006-02-24 | 2008-01-16 | Novartis Ag | New salt |
| SI2146961T1 (sl) | 2007-04-12 | 2014-08-29 | IVAX International GmbH | N-oksidni in/ali di-N-oksidni derivati stabilizatorjev/modulatorjev dopaminskega receptorja, ki izkazujejo izboljšane profile kardiovaskularnih stranskih učinkov |
| US20100197712A1 (en) | 2007-06-18 | 2010-08-05 | Arvid Carlsson | Use of dopamine stabilizers |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| SG188298A1 (en) | 2010-09-03 | 2013-04-30 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| MX347209B (es) | 2011-12-08 | 2017-04-19 | Teva Pharmaceuticals Int Gmbh | La sal de bromhidrato de pridopidina. |
| HK1206297A1 (en) | 2012-04-04 | 2016-01-08 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for combination therapy |
| EP2900226A4 (en) | 2012-09-27 | 2016-03-30 | Teva Pharma | COMBINATION OF RASAGILIN AND PRIDOPIDIN FOR TREATING NEURODEGENERATIVE DISORDERS, ESPECIALLY HUNTINGTON'S DISEASE |
| HK1211525A1 (en) | 2012-09-27 | 2016-05-27 | Teva Pharmaceutical Industries Ltd. | Laquinimod and pridopidine for treating neurodegenerative disorders |
-
2012
- 2012-09-06 CN CN201280043794.9A patent/CN103958469B/zh active Active
- 2012-09-06 KR KR20147009105A patent/KR20140075703A/ko not_active Ceased
- 2012-09-06 US US14/342,253 patent/US9006445B2/en active Active
- 2012-09-06 ES ES12755869.0T patent/ES2639052T3/es active Active
- 2012-09-06 BR BR112014005389A patent/BR112014005389A8/pt not_active IP Right Cessation
- 2012-09-06 EP EP12755869.0A patent/EP2753603B1/en active Active
- 2012-09-06 AU AU2012306386A patent/AU2012306386B2/en not_active Ceased
- 2012-09-06 CA CA 2847736 patent/CA2847736A1/en not_active Abandoned
- 2012-09-06 JP JP2014528965A patent/JP6189299B2/ja not_active Expired - Fee Related
- 2012-09-06 WO PCT/EP2012/067371 patent/WO2013034622A1/en not_active Ceased
- 2012-09-06 EA EA201490569A patent/EA023462B1/ru not_active IP Right Cessation
- 2012-09-06 MX MX2014002731A patent/MX343620B/es active IP Right Grant
-
2014
- 2014-02-25 IL IL231149A patent/IL231149A0/en unknown
- 2014-04-04 ZA ZA2014/02492A patent/ZA201402492B/en unknown
-
2017
- 2017-05-31 JP JP2017107986A patent/JP2017206516A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MX343620B (es) | 2016-11-11 |
| EP2753603A1 (en) | 2014-07-16 |
| BR112014005389A8 (pt) | 2018-04-03 |
| KR20140075703A (ko) | 2014-06-19 |
| JP6189299B2 (ja) | 2017-08-30 |
| US9006445B2 (en) | 2015-04-14 |
| EA201490569A1 (ru) | 2014-09-30 |
| HK1199728A1 (en) | 2015-07-17 |
| WO2013034622A1 (en) | 2013-03-14 |
| MX2014002731A (es) | 2014-04-30 |
| US20140315951A1 (en) | 2014-10-23 |
| EA023462B1 (ru) | 2016-06-30 |
| ES2639052T3 (es) | 2017-10-25 |
| NZ623344A (en) | 2015-10-30 |
| CA2847736A1 (en) | 2013-03-14 |
| JP2014525470A (ja) | 2014-09-29 |
| BR112014005389A2 (pt) | 2017-03-28 |
| AU2012306386B2 (en) | 2017-06-15 |
| IL231149A0 (en) | 2014-04-30 |
| AU2012306386A1 (en) | 2014-04-17 |
| CN103958469B (zh) | 2016-04-20 |
| CN103958469A (zh) | 2014-07-30 |
| JP2017206516A (ja) | 2017-11-24 |
| EP2753603B1 (en) | 2017-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201402492B (en) | Polymorphic form of pridopidine hydrochloride | |
| IL232599A (en) | Hydrobromide salt of peridofidine | |
| EP2596675A4 (en) | METHODS OF MANAGING MULTIPLE TIME ADVANCE GROUPS | |
| HUE047354T2 (hu) | Ivacaftor deuterizált származékai | |
| PL3235812T3 (pl) | Deuterowane pochodne iwakaftoru | |
| SI2707368T1 (sl) | Polimorf linagliptin benzoata | |
| EP2648519A4 (en) | NEW POLYMORPH OF NILOTINIB HYDROCHLORIDE | |
| EP2776393A4 (en) | NAMPT INHIBITORS | |
| PT2751081T (pt) | Forma polimórfica de pitavastatina cálcica | |
| PT2552910E (pt) | Novo polimorfo | |
| GB201121175D0 (en) | Method of electroplating | |
| GB2512737B (en) | Micro-Fermentation of cocoa | |
| EP2680843A4 (en) | DERIVATIVES OF PYRAZOLSUBSTITUTED AMINO-HETEROARYL COMPOUNDS | |
| EP2684869A4 (en) | PREPARATION OF 3-MERCAPOTOPROPIONATES | |
| IL230977A (en) | A crystalline form of relapaldib | |
| ZA201400407B (en) | N-hetero-ring-substituted amide derivative | |
| PL2714707T3 (pl) | Krystalizacja chlorowodorku epirubicyny | |
| GB201113815D0 (en) | Multi-photon isomerisation of transcombretastatins | |
| PL395425A1 (pl) | Sposób wytwarzania chlorowodorku 2-amino-N-tert-butylo-2- cyjanoacetamidu | |
| GB201102475D0 (en) | Method of reducing offset | |
| EP2928469A4 (en) | POLYMORPHIC FORMS OF DESAZADESFERRITHIOCIN ANALOGS | |
| GB201119607D0 (en) | Method of manufacture | |
| GB201108346D0 (en) | Polymorphic form of compound | |
| GB201103839D0 (en) | Polymorphic form | |
| GB201103838D0 (en) | Polymorphic form |